Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)

IND enabling studies underway, with Phase I initiation expected in Q425

Webcast and conference call to be held today at 4:30 pm ET

Isaac Ullatil Joins Wellstack Board, Bringing Visionary Leadership to Advance Healthcare Data Innovation

The physician-owned group expands Houston healthcare services with a multispecialty clinic that puts primary care, cardiology, neurology, lab services, and more all in one place for convenient patient care.   

Ranks in Top 10 Percent of Total Shared Savings

• The Board of Directors approved a maximum cumulative Bitcoin purchase of up to $5 million

• The Company plans to accept payment in digital currencies

Award-winning cosmetic surgery practice recognized for breast augmentation, tummy tuck, and body contouring excellence

• Armah Sports Group is a leading operator in Saudi Arabia, with twelve locations across two brands and additional concepts in development

• CLMBRs are being installed in three of Armah Sports Group's B_FIT nine locations, with a further roll out being planned in the portfolio

• The Saudi Arabia fitness market has doubled since 2017 and is expected to double again by 2027

ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24

ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients with plaque psoriasis in difficult-to-treat areas

Protagonist has earned a $165 million milestone under the terms of recently amended agreement, inclusive of $50 million in accelerated payments

Integrated Outpatient Facilities Struggle with Inadequate RCM Solutions, Leading to Revenue Loss in Labs, Diagnostic Imaging, Rehabilitation, Home Health and Subacute Care

• Dr. Peti Vainio to become Executive Chairman
• Dr. Evis Hursever to become CEO
• Scott Barry to become COO
• Marty Sutter to become Founding Partner

• The Atheltic Business Show features Military and College/High School buyers, which represent some of the biggest customer segments in the fitness equipment industry

• CLMBR has made strong inroads into Military and College/High School, with numerous installations and pilots so far this year

Boston Female Leaders Support Whittier Street Health Center’s Vulnerable and Underserved Women and Families

The U.S. healthcare revenue cycle management (RCM) outsourcing market for outpatient and ancillary services is experiencing significant growth. In 2023, the market sector was valued at approximately USD 6.1 billion. Projections indicate that it will reach USD 24.7 billion by 2030, reflecting a compound annual growth rate (CAGR) of 26.3% during the forecasted period. 

Report Outlines the Realities of Asthma Care in the United States and the Policy and Clinical Interventions that May Provide Improvements to Current Asthma Care

Breaking down the silos between departments opens up an exciting new level of efficiency, cost savings, communication, and faster, more informed decision-making.

• Sea's novel synthetic molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the central nervous system, "the CNS"

  • Two potent, selective, pre-clinical stage molecules are being advanced as possible treatments for three therapeutic indications

• Sea's lead SPM-0404 in investigational new drug-enabling studies for tinnitus, epilepsy, and ALS

  • TCG GreenChem will conduct CMC (Chemistry, Manufacturing, & Controls) development on SPM-0404

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Net Loss and Earnings per Diluted Share of $7.1 million and $1.53

Adjusted EBITDA was a $2.3 million loss, a $1.0 million improvement versus third quarter of 2023

The Company achieved third quarter revenue guidance of $2.0 million, a growth of 325% versus second quarter of 2024

The Company expects to generate $2.4 million in revenue in the fourth quarter of 2024

Stockholders' Equity was $5.8 million at the end of the third quarter of 2024

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial -

- Dermata continues discussions with potential botulinum toxin partners for DMT410 -

- Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 -

Net income of $1.5 million

Adjusted EBITDA¹ of $1.9 million

ADHD Portfolio net revenue up 1% to $15.3 million

Pediatric Portfolio net revenue up 54% sequentially

$20.1 million cash balance at September 30, 2024

Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow

Ryan Selhorn promoted to Chief Financial Officer

Company to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time

Making Veterinary Care More Accessible and Affordable Through Urgent Care-Only Model

Q3 Reimbursements from insurance payors totaled $106,567 an increase of 16.4% sequentially

KindlyMD now provides more than 90% in-network insurance coverage in Utah

Should professionals use bulky recording devices or opt for a compact, wearable solution? The Intelligent Voice Badge offers seamless documentation with cutting-edge AI technology.

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million

• CMTA strengthens its role as the leading force in comprehensive CMT research, forging a new strategic alliance with the Inherited Neuropathy Consortium (INC)
• Together, CMTA and INC are driving research to accelerate the path toward effective treatments for every type of CMT

“Care Anywhere” from CGFNS International now available on major podcast streaming sites 

Being in-network with Aetna and Cigna will now allow Clarity Clinic to expand access to their Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programs, ensuring more individuals receive the high-quality care they need for their recovery journey.

Educational conference focused on diagnosis, research and treatment of rare neuroimmune disorders